drugset / Trial / NCT02603575

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

NCT02603575

Unknown 60 enrolled Beijing Chao Yang Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.

Timeline

Start
2015-11
Primary completion
2020-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 50 mg Intravenous
Subject Prednisone Other / unclassified 20 mg Intravenous

Indications